Melioidosis

disease
On this page

Also known as B pseudomallei infectionBurkholderia pseudomallei caused disease or disorderBurkholderia pseudomallei disease or disorderBurkholderia pseudomallei infectionBurkholderia pseudomallei infectious diseasepseudoglandersWhitmore disease

Summary

Melioidosis (MONDO:0017775) is a disease and 12 clinical trials. Top therapeutic interventions include ceftazidime, meropenem, and co-trimoxazole. A subtype of primary bacterial infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Prevalence: 1-5 / 10 000 (Australia) [Orphanet-validated]
  • Phenotypes (HPO): 23
  • Clinical trials: 12

Clinical features

Epidemiology

Prevalence records

2 prevalence record(s), Orphanet:

TypeClassValueGeographyValidation
Annual incidence1-5 / 10 00050AustraliaValidated
Annual incidence1-5 / 10 00050ThailandValidated

Signs & symptoms

Clinical features (HPO)

23 HPO clinical features (Orphanet curated; top 23 by frequency):

HPO IDTermFrequency
HP:0001945FeverFrequent (30-79%)
HP:0002090PneumoniaFrequent (30-79%)
HP:0011947Respiratory tract infectionFrequent (30-79%)
HP:0011949Acute infectious pneumoniaFrequent (30-79%)
HP:0025044Lung abscessFrequent (30-79%)
HP:0031273ShockFrequent (30-79%)
HP:0031864BacteremiaFrequent (30-79%)
HP:0100806SepsisFrequent (30-79%)
HP:0001743Abnormality of the spleenOccasional (5-29%)
HP:0002758OsteoarthritisOccasional (5-29%)
HP:0003095Septic arthritisOccasional (5-29%)
HP:0012115HepatitisOccasional (5-29%)
HP:0025059Splenic abscessOccasional (5-29%)
HP:0030049Brain abscessOccasional (5-29%)
HP:0031292Cutaneous abscessOccasional (5-29%)
HP:0032162Unusual skin infectionOccasional (5-29%)
HP:0100523Liver abscessOccasional (5-29%)
HP:0100658CellulitisOccasional (5-29%)
HP:0000024ProstatitisVery rare (<1-4%)
HP:0000119Abnormality of the genitourinary systemVery rare (<1-4%)
HP:0000197Abnormal parotid gland morphologyVery rare (<1-4%)
HP:0001886Foot osteomyelitisVery rare (<1-4%)
HP:0011850ParotitisVery rare (<1-4%)

Identifiers

Disease identifiers

FieldValue
Canonical namemelioidosis
Mondo IDMONDO:0017775
MeSHD008554
Orphanet31202
DOIDDOID:5052
ICD-112129350166
NCITC128336
SNOMED CT186312003
UMLSC0025229
MedGen44346
GARD0009546
MedDRA10069748
Is cancer (heuristic)no

Also known as: B pseudomallei infection · Burkholderia pseudomallei caused disease or disorder · Burkholderia pseudomallei disease or disorder · Burkholderia pseudomallei infection · Burkholderia pseudomallei infectious disease · pseudoglanders · Whitmore disease

Disease family

This is a subtype of primary bacterial infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious diseasebacterial infectious diseaseprimary bacterial infectious diseasemelioidosis

Related subtypes (36): Buruli ulcer disease, sennetsu fever, salmonellosis, pinta disease, chancroid, gonorrhea, anthrax infection, leprosy, botulism, diphtheria, tetanus, bartonellosis, brucellosis, campylobacteriosis, glanders, granuloma inguinale, legionellosis, leptospirosis, listeriosis, Mycobacterium avium complex disease, ornithosis, rhinoscleroma, staphyloenterotoxemia, syphilis, cholera, ehrlichiosis, tuberculosis, tularemia, plague, Q fever, shigellosis, Lyme disease, relapsing fever, spirillary rat-bite fever, streptobacillary rat-bite fever, Borrelia miyamotoi disease

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 12.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified10
PHASE41
PHASE21

Top trials by phase / activity

NCTPhaseStatusTitle
NCT01420341PHASE4COMPLETEDCo-trimoxazole as Maintenance Therapy for Melioidosis
NCT05105035PHASE2COMPLETEDOral ARV-1801 Given in Combination With Intravenous Ceftazidime or Meropenem for Treatment of Melioidosis in Hospitalized Patients
NCT07345910Not specifiedNOT_YET_RECRUITINGEnvironment, Pathogens, and Host Interactions in Melioidosis
NCT07358910Not specifiedRECRUITINGRisk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
NCT00579956Not specifiedUNKNOWNA Randomized Double Blinded Comparison of Ceftazidime and Meropenem in Severe Melioidosis
NCT01766830Not specifiedCOMPLETEDRapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever)
NCT02089152Not specifiedCOMPLETEDA Single-blind Stepped Wedge Cluster Randomized Controlled Behaviour Change Trial to Determine Effectiveness of Prevention Programme of Melioidosis in Diabetics in Ubon Ratchathani, Northeast Thailand
NCT02668406Not specifiedCOMPLETEDStudy to Obtain Blood and Voided Urine Samples to Improve the Diagnosis of Melioidosis
NCT03048513Not specifiedUNKNOWNClinical Presentation of Melioidosis in Head and Neck Region
NCT03528265Not specifiedCOMPLETEDAdapting LFI for Melioidosis
NCT04299412Not specifiedCOMPLETEDDiagnostic Accuracy of the DPP II Assay
NCT06089668Not specifiedCOMPLETEDAn Observational Study to Evaluate Clinical Characteristics of Adult Patients With Suspected or Confirmed Melioidosis

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
CEFTAZIDIME41
MEROPENEM41
CO-TRIMOXAZOLE31
CHEMBL474020001